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The aim of this study was to assess the prognostic importance of positive peritoneal cytology in early-stage endometrial cancer. All
278 stage I and 53 stage IIIA (without cervical involvement) endometrial cancer patients operated between 1980 and 1996, recorded
at the Geneva Cancer registry, were included. Stage IIIA cancers were recategorised into ‘cytological’ stage IIIA (positive peritoneal
cytology alone, n¼33) and ‘histological’ stage IIIA (serosal or adnexal infiltration, n¼20). Survival rates were analysed by Kaplan–
Meier method and compared using log-rank test. The prognostic importance of cytology was analysed using a Cox model, accounting
for other prognostic factors. The 5-year disease-specific survival of cytological stage IIIA cancer was similar to stage I (91 vs 92%) and
better than histological stage IIIA cancer (50%, Po0.001). After adjustment for age, myometrial invasion, differentiation and
radiotherapy, cytological stage IIIA patients were still at similar risk to die from endometrial cancer compared to stage I patients
(hazard ratio (HR) 0.7, 95% confidence interval (CI): 0.18–2.3), while histological stage IIIA patients were at a four-fold increased risk
to die from their disease (HR 4.2, 95% CI: 1.7–10.3). This population-based study shows that positive peritoneal cytology in itself has
no impact on survival of patients with localised endometrial cancer. Based on the present and previous studies, FIGO (Fe ´de ´ration
Internationale de Gyne ´cologie et d’Obste ´trique) might consider reviewing its classification system.
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In 1988, FIGO (Fe ´de ´ration Internationale de Gyne ´cologie et
d’Obste ´trique) introduced a new classification system for staging
endometrial cancer, based mainly on surgical findings (Grady and
Ernster, 1996; Burke et al, 1997). In addition to pathological
extension, peritoneal cytology became an important determinant
in this new classification system. In particular, stage I patients (i.e.
endometrial cancer confined to the uterus) and stage II patients
(i.e. endometrial cancer invading the cervix) who demonstrated
positive peritoneal cytology were upstaged to stage IIIA (Konski
et al, 1988). Stage IIIA therefore includes at the same time patients
with positive peritoneal cytology alone and patients with macro-
scopic/histological invasion of serosa or adnexal tissues, suggest-
ing that these patients have similar prognosis.
Since then, some studies suggested that peritoneal cytology is
not an important prognostic factor (Grimshaw et al, 1990; Kadar
et al, 1992; Preyer et al, 2002; Kasamatsu et al, 2003). In a recent
study, including endometrial cancer patients treated with surgery
and radiotherapy, we showed that patients classified as stage IIIA
because of positive peritoneal cytology had the same survival as
stage I endometrial cancer patients (Tebeu et al, 2003). However,
as this hospital-based study included only patients who received
radiotherapy, we could not rule out that the lack of survival
difference was either real or due to the benefit of adjuvant
radiotherapy. In order to study the prognostic importance of
peritoneal cytology, independent of radiation therapy, we extended
our previous study population to nonirradiated patients, using
population-based data.
MATERIALS AND METHODS
The current study was performed with information of the
population based cancer registry of the Swiss canton of Geneva
(approximately 420000 inhabitants). The registry records informa-
tion on all incident cases of malignant neoplasms occurring in the
canton among the resident population. Information is collected
from various sources (i.e. pathology reports, medical files from
public hospitals and private physicians), and is considered very
accurate, confirmed by the very low percentage (o1%) of cases
recorded from death certificates only (Bouchardy, 1997).
The registry systematically records data on sociodemographic
status, diagnostic circumstances, modalities of diagnostic assess-
ment, tumour characteristics coded according to the International
Classification of Diseases for Oncology WHO (1976), stage of the
disease at diagnosis, treatment during the first 6 months after
diagnosis, survival status and cause of death.
Received 9 March 2004; revised 13 May 2004; accepted 17 May 2004;
published online 13 July 2004
*Correspondence: Dr AL Major, Department of Obstetrics and
Gynaecology, Geneva University Hospital, 30 Boulevard de la Cluse,
1211 Geneva 14, Switzerland; E-mail: attila.major@hcuge.ch
British Journal of Cancer (2004) 91, 720–724
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yFor this particular study, we opened the clinical files to obtain
additional data on peritoneal cytological assessment, degree of
myometrial invasion and detail on the type of surgery and
adjuvant radiotherapy. We recoded the stages according to the
1988 FIGO staging system: stage I, tumour confined to uterus;
stage II, tumour invading cervix; stage IIIA, tumour associated
with positive peritoneal cytology or with macroscopic or
histological involvement of serosa or adnexa; and stage IIIBþ,
tumour invading vagina, mucosa of bladder/bowel, regional lymph
node or with distant metastases. For the purpose of the present
study, stage IIIA cancers were further categorised as: ‘cytological’
stage IIIA defined as patients with stage IIIA endometrial cancer
based on positive peritoneal cytology only and ‘histological’ stage
IIIA defined as stage IIIA patients with histological or macroscopic
infiltration of serosa or adnexal tissues.
Other variables of interest were: age at diagnosis (o50, 50–69,
X70 years), period of diagnosis (1980–1987, 1988–1996),
differentiation (good, moderate, poor, unknown), degree of
myometrial invasion (invasion o50%, invasion X50%), type of
surgery (hysterectomy and oophorosalpingectomy with and with-
out lymphadenectomy) and type of radiotherapy (no radiotherapy,
external radiotherapy with brachytherapy, external radiotherapy
only, brachytherapy only). For the purpose of the present study,
patients were regrouped as ‘radiotherapy group’ defined as cases
with any adjuvant radiotherapy and ‘no radiotherapy group’
defined as cases with no adjuvant radiotherapy.
Data on survival and follow-up were derived from the Geneva
cancer registry and included vital status, date of death or departure
from the canton (regularly and systematically obtained from the
Cantonal Population Office) and cause of death (retrieved from
medical files).
Patients
We considered all resident women diagnosed with endometrial
cancer between 1980 and 1996 in the Swiss canton of Geneva
(n¼731). We excluded patients who were not treated surgically
(n¼87), patients with uterine sarcomas (n¼24), patients with
other malignancies occurring within 5 years prior to or within 6
months from endometrial cancer diagnosis (n¼74) and patients
with missing information on histology or stage (n¼7). We also
excluded patients with stage I endometrial cancer without
peritoneal cytological assessment (n¼139). Of the 400 remaining
patients, 278 were diagnosed as stage I, 29 as stage II, 38 as
cytological stage IIIA (33 without and five with cervical involve-
ment), 20 as histological stage IIIA and 35 as stage IIIBþ. For this
study, only patients with stage I, cytological stage IIIA without
Table 1 Characteristics of endometrial cancer patients according to stage at diagnosis
Stage at diagnosis
I ‘Cytological’ IIIA
a ‘Histological’ IIIA Total
n¼278 n¼33 n¼20 n¼331
Characteristics n (%) n (%) n (%) n (%)
Mean age (range) 64.8 (33–90) 65.8 (48–85) 68.0 (48–83) 65.1 (33–91)
Age category (years)
o50 18 (7) 1 (3) 1 (5) 20 (6)
50–69 170 (61) 21 (64) 12 (60) 203 (61)
70+ 90 (32) 11 (33) 7 (35) 108 (33)
Period of diagnosis
1980–87 129 (46) 9 (27) 7 (35) 145 (44)
1988–96 149 (54) 24 (73) 13 (65) 186 (56)
Invasion of myometrium
o50% 211 (76) 18 (55) 4 (20) 233 (70)
X50% 63 (23) 15 (45) 16 (80) 94 (28)
Unknown 4 (1) — — 4 (1)
Differentiation
Good 176 (63) 15 (45) 7 (35) 198 (60)
Moderate 63 (23) 12 (36) 5 (25) 80 (24)
Poor/undifferentiated 28 (10) 4 (12) 7 (35) 39 (12)
Unknown 11 (4) 2 (6) 1 (5) 14 (4)
Surgical procedure
Hysterectomy 12 (4) — — 12 (4)
Hysterectomy and annexectomy
b 247 (89) 33 (100) 19 (95) 299 (90)
Hysterectomy, annexectomy
b and lymphadenectomy 4 (1) — 1 (5) 5 (2)
Unspecified type of surgery 15 (5) — — 15 (5)
Radiotherapy
None 149 (54) 6 (18) 5
c (25) 160 (48)
External and brachy 46 (17) 14 (42) 11 (55) 71 (22)
External only 10 (4) 9 (27) 4 (20) 23 (7)
Brachy only 72 (26) 4 (12) — 76 (23)
Unknown type 1 (o1) — — 1 (o1)
aExcluding patients with cervical invasion.
bNine patients had unilateral annexectomy and seven had previous unilateral annexectomy because of cysts or extrauterine gravities.
One 41-year-old patient had only one ovary removed and the other left in place because of her young age and in one patient the reason was unknown.
cOne of these patients
received adjuvant chemotherapy.
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cancer were included (n¼331).
Peritoneal washing was performed by either collecting liquid
present in the peritoneal cavity or by rinsing the cavity with
100cm
3 of physiological saline. The liquid was centrifuged and
assessed for the presence of malignant cells. A patient was
considered to have positive peritoneal cytology if adenocarcinoma
cells were detected, regardless of the number of cancer cells.
Surgical treatment included hysterectomy generally including
oophorosalpingectomy. Lymphadenectomy was not routinely
performed.
Statistical analyses
The 5-year disease-specific survival rates were calculated con-
sidering death from endometrial cancer only by Kaplan–Meier
method and compared by nonparametric survival analyses using
log-rank test. The effect of peritoneal cytology on endometrial
cancer mortality was analysed by multivariate Cox’s proportional-
hazards modelling, taking into account other variables signifi-
cantly linked to survival. Analyses were performed using SPSS
(Hull and Nie, 1995). Differences were considered statistically
significant at Po0.05. Additional subgroup analyses were per-
formed among patients with and without additional radiotherapy.
RESULTS
Patient and tumour characteristics and treatment modalities of the
stage I (n¼278), cytological stage IIIA without cervical involve-
ment (n¼33) and histological stage IIIA (n¼20) patients are
described in Table 1. Compared to stage I patients, women with
histological stage IIIA cancer were slightly older, had less well-
differentiated tumours and had more often myometrial invasion of
more than 50%. Cytological stage IIIA tumours were less
differentiated and invaded the myometrium to a deeper extent.
Overall, 171 (52%) women underwent adjuvant radiotherapy. In
all, 46% (n¼129) of stage I patients had radiotherapy compared to
83% (n¼27) of cytological stage IIIA and 75% (n¼15) of
histological stage IIIA patients.
Figure 1 presents the 5-year disease-specific survival curves
according to stage. For all patients combined (with and without
adjuvant radiotherapy), survival for stage I endometrial cancer
(92.3%) was comparable to that of cytological stage IIIA
endometrial cancer (90.9%). In contrast, patients with histological
stage IIIA cancer had a significantly worse survival (49.5%,
Po0.001). When separately analysing patients with and without
adjuvant radiotherapy, similar results were observed (Figure 1B
and C). There was still no disease-specific survival difference
between stage I and cytological stage IIIA cancer patients and a
lower survival rate for histological stage IIIA patients.
Table 2 presents the 5-year disease-specific survival rates and
the adjusted risks (hazard ratio’s) of endometrial cancer mortality
for stage, myometrial invasion, differentiation and radiotherapy.
After adjustment for age, tumour differentiation, myometrial
invasion and radiotherapy, cytological stage IIIA patients were not
at an increased risk to die from endometrial cancer compared to
patients with stage I disease (hazard ratio (HR) 0.7, 95%
confidence interval (CI): 0.2–2.3). Histological stage IIIA patients,
however, had a four-fold increased risk to die from their disease
(HR 4.2, 95% CI: 1.7–10.3). Also, moderate or poor tumour
differentiation significantly and independently increased the risk
to die of endometrial cancer (adjusted HR 4.6, 95% CI: 1.7–12.3,
and 9.8, 95% CI: 3.6–26.8, respectively). Myometrial invasion and
radiotherapy were not significantly and independently linked to
endometrial cancer mortality.
A total of 15 patients had clear cell carcinoma (n¼7) or
papillary serous carcinoma (n¼8). Three (20%) were categorised
as cytological stage IIIa. Excluding these 15 patients from the
analyses did not significantly modify the results.
DISCUSSION
In a recent publication, we have shown that positive peritoneal
cytology was not a prognostic factor for patients with early-stage
endometrial cancer treated with radiotherapy (Tebeu et al, 2003).
We could, however, not rule out that the high survival of
cytological stage IIIA patients was due to the use of radiotherapy,
because in this study we included only irradiated patients. We
therefore decided to extend our study population to all operated
women, treated or not by radiotherapy. The present study
confirms our earlier findings and shows that patients with
‘cytological stage IIIA’ endometrial cancer have the same
prognosis as stage I patients, also after adjusting for other
important prognostic factors, such as myometrial invasion, grade
and, in particular, use of radiotherapy. In addition, similar
prognosis of women with stage I and cytological stage IIIA
endometrial cancer was observed among women with and without
radiotherapy.
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Figure 1 Disease-specific survival curves of endometrial cancer accord-
ing to stage – stage I, cytological stage IIIA (without cervical invasion),
histological stage IIIA – for all patients (A), patients who did not receive
radiotherapy (B) and patients who received radiotherapy (C).
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peritoneal cytology and unfavourable prognostic factors (lymph
node invasion, grade, myometrial invasion, etc.) (Creasman et al,
1981; Ide, 1984), FIGO (2000) decided to incorporate cytology
in its classification system, upgrading stage I and stage II patients
with positive peritoneal cytology to stage IIIA (Creasman et al,
1987).
Since then, three studies confirmed the importance of peritoneal
cytology by showing that patients with early-stage endometrial
cancer with positive peritoneal cytology had worse survival rates
than patients with early-stage endometrial cancer with negative
peritoneal cytology (Harouny et al, 1988; Morrow et al, 1991;
Obermair et al, 2001). As these studies classified patients according
to the clinical staging system (AJCC, 2002) (based on hysterometry
and physical examination), other important prognostic factors like
myometrial invasion (Creasman et al, 1987) were not taken into
account. As a result, positive cytology appeared to be an
independent prognostic factor, while in fact it is more likely a
consequence of aggressive or more advanced cancer. This goes
along with our own findings, where tumours with deeper invasion
and poor differentiation were associated more often with positive
peritoneal cytology. In addition, these studies did not present the
number of patients with cervical involvement and an unequal
distribution of this important prognostic parameter between
patients with and without positive cytology might have influenced
prognosis.
Five publications used the new FIGO surgical staging system to
investigate the prognostic effect of positive peritoneal cytology. All
five pointed in the same direction and suggested that positive
peritoneal cytology is not an independent prognostic factor in
endometrial cancer, that is, some studies showed no survival
difference between stage I and cytological stage IIIA cancer
(Grimshaw et al, 1990; Kadar et al, 1992; Kasamatsu et al, 2003;
Tebeu et al, 2003) and others showed an important survival
difference within stage IIIA patients, that is, significantly better
prognosis of cytological stage IIIA patients over histological stage
IIIA patients (Preyer et al, 2002; Tebeu et al, 2003). These studies
had several shortcomings. Several were not able to adjust for use of
radiotherapy, making it difficult to estimate the effect of peritoneal
cytology in itself (Grimshaw et al, 1990; Kadar et al, 1992; Preyer
et al, 2002; Tebeu et al, 2003). Some studies included patients with
cervical involvement, but did not adjust for the possible impact of
this prognostic factor (Kadar et al, 1992; Preyer et al, 2002;
Kasamatsu et al, 2003).
In the present study, we have eliminated most of the problems of
the other studies. We included stage I and both cytological and
histological stage IIIA patients. We used surgical staging, which
enabled us to adjust for prognostic factors such as grade and
myometrial invasion. In addition, we included both patients with
and without radiotherapy and we were able to adjust for this
variable as well. In addition, patients with cervical invasion were
excluded, making the results easy to interpret. There is no survival
difference between patients with stage I endometrial cancer and
stage IIIA endometrial cancer based on positive peritoneal
cytology alone, even after adjusting for other prognostic factors.
This strongly suggests that positive peritoneal cytology is not an
independent prognostic factor in patients with endometrial cancer.
We acknowledge that our study suffered from a relatively low
statistical power due to the limited number of patients with
cytological and histological stage IIIA endometrial cancer. In
particular, subgroup analyses according to the use of radiotherapy
were based on low patient numbers, and we therefore cannot give a
definitive conclusion on the lack of benefit of radiotherapy among
early endometrial cancer patients with positive peritoneal cytology.
Additional research on the usefulness of radiotherapy for this
particular patient category might be indicated. Nevertheless, this
study confirms previous studies and strongly suggests that the
1988 FIGO classification system classifies patients with cancer
confined to the uterus and with positive peritoneal cytology alone
into an inappropriate risk category. Owing to the present and
previous studies, FIGO might consider reviewing its 1988
classification system.
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Table 2 Disease-specific survival and hazard ratios for death from endometrial cancer according to stage
n
Endometrial
cancer deaths (n)
5-year disease-specific
survival (%)
Crude HR
a
(95% CI)
Adjusted HR
b
(95% CI)
Stage
Stage I 278 20 92.3 1
c 1
c
Cytological stage IIIA
d 33 3 90.9 1.3 (0.4–4.3) 0.74 (0.2–2.3)
Histological stage IIIA 20 10 49.5 10.5 ***(4.8–22.7) 4.2 **(1.7–10.3)
Myometrial invasion
o50%
e 236 1
c 1
c
X50% 95 3.5 ***(1.7–7.1) 1.8 (0.8–3.9)
Differentiation
Good 198 1
c 1
c
Moderate 80 5.3 ***(2.0–14.1) 4.6 **(1.7–12.3)
Poor 39 15.0 ***(5.7–39.0) 9.8 ***(3.6–26.8)
Unknown 14 2.7 (0.3–22.0) 2.8 (0.3–23.4)
Radiotherapy
No 160 1
c 1
c
Yes 171 2.7 *(1.3–5.8) 1.7 (0.7–4.0)
HR¼hazard ratio; CI¼confidence interval. *Po0.05, **Po0.01, ***Po0.001.
aOnly adjusted for age (continuous).
bAlternately adjusted for age (continuous), stage, tumour
differentiation, myometrial invasion and radiotherapy.
cReference category.
dExcluding patients with cervical invasion.
eIncluding four patients (o1%) with unknown degree of
myometrial invasion.
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